<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01554696</url>
  </required_header>
  <id_info>
    <org_study_id>015K-CL-RA21</org_study_id>
    <secondary_id>2011-006018-15</secondary_id>
    <nct_id>NCT01554696</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate</brief_title>
  <official_title>A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of ASP015K in moderate to
      severe rheumatoid arthritis subjects who are methotrexate-inadequate responders (MTX-IR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects in each treatment group will continue to take their concomitant oral weekly dose of
      methotrexate (MTX) in addition to daily ASP015K or matching placebo, taken orally with food,
      daily for 12 weeks after randomization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects achieving American College of Rheumatology Criteria 20 (ACR 20) response</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough plasma concentration of ASP015K and metabolite(s)</measure>
    <time_frame>up to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving ACR 50 response</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving ACR 70 response</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Disease Activity Score using 28 joint count and C Reactive Protein (DAS28-CRP)</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">379</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>ASP015K lowest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP015K lowest dose daily in addition to concomitant weekly oral methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP015K low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP015K low dose daily in addition to concomitant weekly oral methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP015K medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP015K medium dose daily in addition to concomitant weekly oral methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP015K high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP015K high dose daily in addition to concomitant weekly oral methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily in addition to concomitant weekly oral methotrexate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP015K</intervention_name>
    <description>oral</description>
    <arm_group_label>ASP015K lowest dose</arm_group_label>
    <arm_group_label>ASP015K low dose</arm_group_label>
    <arm_group_label>ASP015K medium dose</arm_group_label>
    <arm_group_label>ASP015K high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has rheumatoid arthritis (RA) diagnosed according to the 1987 revised ACR
             criteria for at least 6 months prior to Screening

          -  Subject has been treated with oral methotrexate (MTX) for a minimum of 90 days and at
             a stable dose for 28 days prior to the first dose of study drug

          -  ≥6 tender/painful joints; ≥6 swollen joints

          -  Subject meets the ACR 1991 Revised Criteria for Global Functional Status in RA Class
             I, II or III at Screening and Baseline

          -  Subject's other medication taken for treatment of RA must be stable for at least 28
             days prior to start of the study

          -  Male and female subjects must be willing to comply with contraception requirements as
             well as restrictions regarding egg and sperm donation

          -  Female subject must not be breastfeeding at Screening or during the study period, and
             for 60 days after the final study drug administration

          -  Subject agrees not to participate in another interventional study while on treatment

        Exclusion Criteria:

          -  Positive Mycobacterium tuberculosis (TB) test within 90 days of Screening

          -  Abnormal chest x-ray indicative of an acute or chronic infectious process or
             malignancy

          -  Receipt of live or live attenuated virus vaccination within 30 days prior to the first
             dose of study drug

          -  Known history of positive test for hepatitis B surface antigen (HBsAg) or hepatitis C
             antibody or history of a positive test for human immunodeficiency virus (HIV)
             infection

          -  History of any other autoimmune rheumatic disease, other than Sjogren's syndrome

          -  Previous history of clinically significant infections or illness (requiring
             hospitalization or requiring parenteral therapy) within 90 days of the Baseline visit,
             or a history of any illness that would preclude participation in the study

          -  History of any malignancy, except for successfully treated basal or squamous cell
             carcinoma of the skin or in-situ carcinoma of the cervix

          -  Does not meet specified washout criteria for the following RA medications: gold,
             azathioprine, minocycline, penicillamine, etanercept, certolizumab, adalimumab,
             golimumab, infliximab, cyclophosphamide, and leflunomide

          -  Subject has previously used a non anti-TNF biologic disease-modifying antirheumatic
             drug (DMARD) (e.g., anakinra, abatacept, rituximab, tocilizumab)

          -  Previous intolerance to Janus kinase (JAK) inhibitors

          -  Receipt of intra-articular or parenteral corticosteroid within 28 days prior to the
             first dose of study drug or is currently taking &gt; 30 mg oral morphine (or narcotic
             equivalent) per day

          -  Absolute lymphocyte count (ALC) &lt; 750/mm3

          -  Receipt of plasma exchange therapy within 60 days prior to the start of study drug

          -  Receipt of any investigational agent within 30 days or 5 half-lives, whichever is
             longer, prior to first dose of study drug

          -  Receipt of medications that are CYP3A substrates with narrow therapeutic range within
             14 days prior to first dose of study drug

          -  History of heart failure, defined as New York Heart Association (NYHA) grade 3 or
             greater

          -  History of long QT syndrome or prolonged QT interval

          -  Any ongoing severe, progressive, or uncontrolled renal, hepatic, hematological,
             gastrointestinal, metabolic, endocrine, pulmonary, cardiac, neurological, or
             infectious disease, or any ongoing illness which would make the subject unsuitable for
             the study. This includes stomatitis, gastrointestinal ulcers, or any other condition
             that would preclude continued treatment with methotrexate

          -  Subject has any condition possibly affecting oral absorption (e.g., gastrectomy, other
             malabsorption syndromes, or clinically significant diabetic gastroenteropathy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Medical Director Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Talbert Group</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>LaJolla</city>
        <state>California</state>
        <zip>92093-0943</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Medical Advances</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Arthritis Center Medical Group</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Associates of Colorado Springs</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Associates</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Bone &amp; Joint</name>
      <address>
        <city>Morton Grove</city>
        <state>Illinois</state>
        <zip>60053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deerbrook Medical Asssociates</name>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <zip>60061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Arthritis and Osteoporosis</name>
      <address>
        <city>Elizabethtown</city>
        <state>Kentucky</state>
        <zip>42701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clincal Research Center of Reading</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Consultants, PLLC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909-1907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Rheumatology Research PA</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Arthritis &amp; Rheumatic Disease, P.C.</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain State Clinical Research</name>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <zip>26301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moliere Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1190</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Burgas</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Plovdiv AD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Sv. Ivan Rilski&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPS Rodrigo Botero SAS</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>5001000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral de Reumatología del Caribe S.A.S</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral De Reumatologia E Inmunologia</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicity Sas</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servimed E.U.</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de medicina Interna Julian Coronel</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav</name>
      <address>
        <city>Praha 2</city>
        <zip>128 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDICAL PLUS, s.r.o. or REVMACENTRUM UH, s.r.o.</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>68601</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PV-MEDICAL s.r.o.</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRC Gyogyszervizsgalo Kozpont Kft</name>
      <address>
        <city>Balatonfured</city>
        <zip>H-8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rethy Pal Korhaz es Rendelointezet</name>
      <address>
        <city>Bekescsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revita Clinic Rheumatology</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenezy Hospital Institute of Clinical Pharmacology</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morales Vargas Centro de Investigacion, SC Rheumatology</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <zip>37000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde Gutierrez</name>
      <address>
        <city>Guadalajara</city>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Javier Orozco Alcala Private Doctor´s office</name>
      <address>
        <city>Guadalajara</city>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliditer S.A. de C.V.Huerta S.I.</name>
      <address>
        <city>Mexico D.F.</city>
        <zip>6700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clinica de Morelia, S.C.</name>
      <address>
        <city>Morelia</city>
        <zip>58070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Osteo-Medic sc A. Racewicz, J. Supronik</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Osteoporozy i Chorob KKostno-Stawowych Daniluk Clinical Research Centre</name>
      <address>
        <city>Bialystok</city>
        <zip>15-461</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr. 2 im. Dr. Jana Biziela</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Medyczne ProMiMed</name>
      <address>
        <city>Krakow</city>
        <zip>31-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zespol Poradni Specjalistycznych REUMED sp. Zo.o</name>
      <address>
        <city>Lublin</city>
        <zip>20-582</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARS Rheumatica</name>
      <address>
        <city>Warszawa</city>
        <zip>02-653</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheuma Medicus Zaktad Opieki Zdrowotnej Relle Brkolozka</name>
      <address>
        <city>Wraszawa</city>
        <zip>02-118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2012</study_first_submitted>
  <study_first_submitted_qc>March 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <disposition_first_submitted>December 1, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>December 1, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 16, 2014</disposition_first_posted>
  <last_update_submitted>December 1, 2014</last_update_submitted>
  <last_update_submitted_qc>December 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>ASP015K</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

